Clinical Trials and Studies
In line with unparalleled personalized care for our patient guests, VRCCO is dedicated to advancing veterinary medicine through clinical research and trials. Through collaborations with clinical research organizations, universities and private industry, we are able to apply promising, cutting-edge treatments to our patients while accumulating data that may help future patient guests, both here at VRCCO and as a whole across the country and world.
Clinical Trials Now Enrolling
HEMANGIOSARCOMA CLINICAL STUDY ANNOUNCEMENT:
Now Enrolling Dogs with Splenic Hemangiosarcoma Post-Splenectomy
Veterinary Referral Center of Central Oregon is now enrolling dogs with Stage I or II splenic hemangiosarcoma (HSA) that have recently undergone splenectomy. Patients are candidates for screening as long as they can initiate study treatment within 30 days of splenectomy and have not received cancer therapy to date. The study is fully funded. Enrolled patients will receive 4 doses of Paccal Vet® chemotherapy and will be monitored for up to 12 months following splenectomy.
Paccal Vet is a proprietary formulation of paclitaxel that is being developed to be better tolerated by veterinary patients. The conventional formulation of paclitaxel (Taxol®) is associated with acute adverse reactions in dogs, which has largely precluded the use of paclitaxel as a chemotherapeutic in veterinary oncology. Paclitaxel is one of the most effective anticancer agents used in human cancer today, with potent activity against a wide variety of tumors. While anti-tumor activity has been documented in other cancers in dogs, studies have not yet been performed in hemangiosarcoma. This study seeks to test whether Paccal Vet is safe for use in dogs with hemangiosarcoma and whether the drug may improve their survival.
Each patient will be actively participating in the study for up to 12 months from the time of splenectomy or until disease progression. Enrolled patients will receive a total of 4 doses of Paccal Vet, administered 3 weeks apart. Enrollment benefits include all costs associated with treatment as well as diagnostics, including lab work, imaging (x-rays and ultrasound) and examinations during the study.
FELINE CANCER STUDY ANNOUNCEMENT:
Now enrolling cats with any measurable tumor type for a chemotherapy clinical trial
Veterinary Referral Center of Central Oregon is now enrolling cats with any solid tumor type that may be amenable to treatment with chemotherapy. Patients are candidates for screening even if they have received prior chemotherapy or other cancer treatments as long as they have not received any chemotherapy or radiation therapy within 3 weeks of starting the study. The study is fully funded. Enrolled patients will receive up to 4 doses of Paccal Vet® chemotherapy and tolerability and response to treatment will be monitored.
Paccal Vet is a proprietary formulation of paclitaxel that is being developed to be better tolerated by veterinary patients. The conventional formulation of paclitaxel (Taxol®) is associated with acute adverse reactions in dogs, which has largely precluded the use of paclitaxel as a chemotherapeutic in veterinary oncology. Paclitaxel is one of the most effective anticancer agents used in human cancer today, with potent activity against a wide variety of tumors. These studies seek to test whether PaccalVet is safe for use in dogs and cats, and whether it has antitumor activity against certain cancers.
Cats enrolled in the study will receive Paccal Vet via intravenous infusion over 15-30 minutes once every 3 weeks for up to four doses. Throughout those treatment cycles, cats will be monitored carefully for tumor responses and adverse events through physical examinations, blood work, and quality of life questionnaires. Enrollment benefits include all costs associated with treatment as well as diagnostics, including lab work, imaging (x-rays and ultrasound) and examinations during the study.
For more information, please contact the Oncology Department at VRCCO: kcouto@vrcvet.com
This study has been reviewed and approved by an ethical review board and will be conducted in compliance with VICH-GCP guidelines. It is being run by CASTR Alliance Inc., a veterinary clinical research organization. Enrollment in this study is voluntary.
VRCCO Oncology is located at our Emergency & Specialty Veterinary Hospital in Bend. To learn more please call 541-209-6960 or email us at info@vrcvet.com.
VRCCO Oncology
62889 NE Oxford Ct.
Bend, Oregon 97701
541-209-6960